Translational Therapeutic Delivery
Innovation Laboratory
The current landscape of biomedical challenges necessitates a multi-disciplinary approach, integrating advancements in biological sciences with engineering and computational technologies. The focus on developing disease-modifying and personalized therapeutics aligns with the growing understanding of diseases at a molecular level. This, coupled with the need for targeted delivery systems, underscores the importance of collaboration across various scientific domains. Innovations in material science and engineering to precisely target diseased cells without affecting healthy ones are crucial. The convergence of these diverse fields holds the promise for groundbreaking therapies that can meet the complex demands of modern medicine.
The current landscape of biomedical challenges necessitates a multi-disciplinary approach, integrating advancements in biological sciences with engineering and computational technologies. The focus on developing disease-modifying and personalized therapeutics aligns with the growing understanding of diseases at a molecular level. This, coupled with the need for targeted delivery systems, underscores the importance of collaboration across various scientific domains. Innovations in material science and engineering to precisely target diseased cells without affecting healthy ones are crucial. The convergence of these diverse fields holds the promise for groundbreaking therapies that can meet the complex demands of modern medicine.
The specific distinctions of TTD-IL services include:
- Commitment to open communication and the establishment of strategic partnerships that capitalize on the strengths of both parties involved.
- Employing full-time PhD level scientists dedicated to supporting research and development, ensuring continuity in their efforts.
- Meticulous experimental design and the implementation of validated standard operating procedures to guarantee reproducibility.
- Maintaining confidentiality in creating data packages tailored to their partners, while safeguarding intellectual property assets.
- Efficient timelines and measurable milestones, which facilitate informed go/no-go decisions and contribute to the de-risking of investments.
The TTD-IL model is designed to offer specialized expertise in early-stage formulation development, providing the flexibility necessary to experiment with various conditions and fine-tune parameters. This approach is distinct from traditional CRO or CMO models, which may not offer the same level of adaptability in the early phases of development. By collaborating with Northeastern University, TTD-IL taps into a broad spectrum of research and technological capabilities across various colleges, benefiting from a robust research infrastructure equipped with cutting-edge facilities and equipment essential for drug discovery and development processes.
Furthermore, TTD-IL’s partnerships with established CROs like Charles River Labs and Ascendia Pharmaceuticals enhance its ability to push forward technological advancements into critical stages such as large animal studies, GLP-compliant toxicology and safety assessments, as well as GMP-compliant manufacturing and scaling operations. The integration with a comprehensive network of clinical research facilities and academic medical centers positions TTD-IL favorably to transition into first-in-human clinical trials.
For further information about TTD-IL, our capabilities, and specific collaborative project ideas,
Please contact: Mansoor M. Amiji, PhD; University Distinguished Professor, Northeastern University, 360 Huntington Avenue, 140 The Fenway Building, Boston, Massachusetts 02115.
Tel: 617-839-9679
Email: m.amiji@northeastern.edu